Roles of P-glycoprotein and multidrug resistance protein in transporting para-aminosalicylic acid and its N-acetylated metabolite in mice brain

Acta Pharmacologica Sinica

Volumn 35, Issue 12, 2014, Pages 1577-1585

  Hong, Lan ^a,b   Xu, Cong ^a   O'Neal, Stefanie ^b   Bi, Hui Chang ^c   Huang, Min ^c   Zheng, Wei ^b   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b PURDUE UNIVERSITY   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

blood brain barrier; chelating agent; manganism; MDCK MDR1 cells; MDCK MRP1 cells; MK 571; multidrug resistance protein; P glycoprotein; para aminosalicylic acid

Indexed keywords

AMINOSALICYLIC ACID; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; VERLUKAST; ACETYL 4-AMINOSALICYLIC ACID; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; AMINOSALICYLIC ACID DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN CAPILLARY; BRAIN METABOLISM; BRAIN PARENCHYMA; COMPETITIVE INHIBITION; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; MALE; MDCK CELL LINE; MOUSE; NONHUMAN; PARENCHYMA; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; BLOOD; BRAIN; CAPILLARY PERMEABILITY; DEFICIENCY; DOG; DRUG EFFECTS; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; METABOLISM; TISSUE DISTRIBUTION;

ACETYLATION; AMINOSALICYLIC ACID; AMINOSALICYLIC ACIDS; ANIMALS; BIOTRANSFORMATION; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; DOGS; INJECTIONS, INTRAVENOUS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MEMBRANE TRANSPORT MODULATORS; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 84949131655     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2014.103     Document Type: Article

References (50)

1. Aschner M, Guilarte TR, Schneider JS, Zheng W. Manganese: recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol 2007; 221: 131-47.
2. Bowler RM, Gysens S, Diamond E, Nakagawa S, Drezgic M, Roels HA. Manganese exposure: neuropsychological and neurological symptoms and effects in welders. Neurotoxicology 2006; 27: 315-26.
3. Crossgrove J, Zheng W. Manganese toxicity upon overexposure. NMR Biomed 2004; 17: 544-53.
4. Myers JE, Thompson ML, Ramushu S, Young T, Jeebhay MF, London L, et al. The nervous system effects of occupational exposure on workers in a South African manganese smelter. Neurotoxicology 2003; 24: 885-94.
5. Calne DB, Chu NS, Huang CC, Lu CS, Olanow W. Manganism and idiopathic parkinsonism: similarities and differences. Neurology 1994; 44: 1583-6.
6. Cook DG, Fahn S, Brait KA. Chronic manganese intoxication. Arch Neurol 1974; 30: 59-64.
7. Ono K, Komai K, Yamada M. Myoclonic involuntary movement associated with chronic manganese poisoning. J Neurol Sci 2002; 199: 93-6.
8. Seaton CL, Lasman J, Smith DR. The effects of CaNa2EDTA on brain lead mobilization in rodents determined using a stable lead isotope tracer. Toxicol Appl Pharmacol 1999; 159: 153-60.
9. Hernandez E, Discalzi G, Valentini C, Venturi F, Chio A, Carmellino C, et al. Follow-up of patients affected by manganese-induced Parkinsonism after treatment with CaNa2EDTA. Neurotoxicology 2006; 27: 333-9.
10. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcantara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003; 348: 119-28.
11. Ky SQ, Deng HS, Xie PY, Hu W. A report of two cases of chronic serious manganese poisoning treated with sodium para-aminosalicylic acid. Br J Ind Med 1992; 49: 66-9.
12. Jiang YM, Mo XA, Du FQ, Fu X, Zhu XY, Gao HY, et al. Effective treatment of manganese-induced occupational Parkinsonism with p-aminosalicylic acid: a case of 17-year follow-up study. J Occup Environ Med 2006; 48: 644-9.
13. Nelson M, Huggins T, Licorish R, Carroll MA, Catapane EJ. Effects of p-aminosalicylic acid on the neurotoxicity of manganese on the dopaminergic innervation of the cilia of the lateral cells of the gill of the bivalve mollusc, Crassostrea virginica. Comp Biochem Physiol C Toxicol Pharmacol 2010; 151: 264-70.
14. Shi XY. One case on chronic serious manganism treated with sodium para-aminosalicylic acid. J Baotou Med Coll 2002; 18: 161.
15. Wu P. A report of one case on the diagnostic treatment with PAS-Na. Ind Health Occup Dis 1991; 17: 163.
16. Yoon H, Kim DS, Lee GH, Kim JY, Kim DH, Kim KW, et al. Protective effects of sodium para-amino salicylate on manganese-induced neuronal death: the involvement of reactive oxygen species. J Pharm Pharmacol 2009; 61: 1563-9.
17. Zhao DF. The clinical observation on manganism treated with PAS-Na. J Guiyang Med Coll 1995; 20: 327.
18. Zheng W, Jiang YM, Zhang Y, Jiang W, Wang X, Cowan DM. Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats. Neurotoxicology 2009; 30: 240-8.
19. Santos AP, Lucas RL, Andrade V, Mateus ML, Milatovic D, Aschner M, et al. Protective effects of ebselen (Ebs) and para-aminosalicylic acid (PAS) against manganese (Mn)-induced neurotoxicity. Toxicol Appl Pharmacol 2012; 258: 394-402.
20. Santos D, Batoreu MC, Aschner M, Marreilha dos Santos AP. Comparison between 5-aminosalicylic acid (5-ASA) and para-aminosalicylic acid (4-PAS) as potential protectors against Mn-induced neurotoxicity. Biol Trace Elem Res 2013; 152: 113-6.
21. Hong L, Jiang W, Pan H, Jiang Y, Zeng S, Zheng W. Brain regional pharmacokinetics of p-aminosalicylic acid and its n-acetylated metabolite: effectiveness in chelating brain manganese. Drug Metab Dispos 2011; 39: 1904-9.
22. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25.
23. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009; 31: 497-511.
24. Zheng W, Aschner M, Ghersi-Egea JF. Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol 2003; 192: 1-11.
25. Zheng W, Monnot AD. Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol Ther 2012; 133: 177-88.
26. Daood M, Tsai C, Ahdab-Barmada M, Watchko JF. ABC transporter (Pgp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008; 39: 211-8.
27. Baehr C, Reichel V, Fricker G. Choroid plexus epithelial monolayers-a cell culture model from porcine brain. Cerebrospinal Fluid Res 2006; 3: 13.
28. Klas J, Wolburg H, Terasaki T, Fricker G, Reichel V. Characterization of immortalized choroid plexus epithelial cell lines for studies of transport processes across the blood-cerebrospinal fluid barrier. Cerebrospinal Fluid Res 2010; 7: 11-22.
29. Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76: 22-76.
30. Spector R. Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J Neurochem 2010; 112: 13-23.
31. Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 2003; 55: 83-105.
32. USFDA (2012). Draft guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling.
33. Hong L, Jiang W, Zeng S, Zheng W. HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues. J Pharm Biomed Anal 2011; 54: 1101-9.
34. Deane R, Zheng W, Zlokovic BV. Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain, J Neurochem 2004; 88: 813-20.
35. Liu Y, Yu CN, Zeng S. Establishment of madin-darby canine kidney cell line with high P-glycoprotein expression. Chin Pharm J 2009; 44: 1608-13.
36. Rhoton AL Jr. The cerebrum. Anatomy. Neurosurgery 2007; 61: 37-118.
37. Schmahmann JD. Vascular syndromes of the thalamus. Stroke 2003; 34: 2264-78.
38. Huo X, Liu Q, Wang C, Meng Q, Sun H, Peng J, et al. Enhancement effect of P-gp inhibitors on the intestinal absorption and antiproliferative activity of bestatin. Eur J Pharm Sci 2013; 50: 420-8.
39. Wang L, Meng Q, Wang C, Liu Q, Peng J, Huo X, et al. Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistant human leukemia K562/adriamycin cells by down-regulating MDR1 via a mechanism involving NF-κB signaling inhibition. J Nat Prod 2013; 76: 909-14.
40. Huo X, Liu Q, Wang C, Meng Q, Sun H, Peng J, et al. Inhibitory effect of valsartan on the intestinal absorption and renal excretion of bestatin in rats. J Pharm Sci 2014; 103: 719-29.
41. Liu Q, Wang C, Meng Q, Huo X, Sun H, Peng J, et al. MDR1 and OAT1/OAT3 mediate the drug-drug interaction between puerarin and methotrexate. Pharm Res 2014; 31: 1120-32.
42. Bock NA, Paiva FF, Nascimento GC, Newman JD, Silva AC. Cerebrospinal fluid to brain transport of manganese in a non-human primate revealed by MRI. Brain Res 2008; 1198: 160-70.
43. Lai JC, Minski MJ, Chan AW, Leung TK, Lim L. Manganese mineral interactions in brain. Neurotoxicology 1999; 20: 433-44.
44. Li GJ, Choi BS, Wang X, Liu J, Waalkes MP, Zheng W. Molecular mechanism of distorted iron regulation in the blood-CSF barrier and regional blood-brain barrier following in vivo subchronic manganese exposure. Neurotoxicology 2006; 27: 737-44.
45. Reaney SH, Bench G, Smith DR. Brain accumulation and toxicity of Mn(II) and Mn(III) exposures. Toxicol Sci 2006; 93: 114-24.
46. 2) on the absorption and cerebral distribution of manganese in rats. Arch Toxicol 1997; 71: 223-30.
47. Zheng W, Zhao Q, Slavkovich V, Aschner M, Graziano JH. Alteration of iron homeostasis following chronic exposure to manganese in rats. Brain Res 1999; 833: 125-32.
48. Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 2011; 8: 3.
49. Spector R, Lorenzo AV. The active transport of para-aminosalicylic acid from the cerebrospinal fluid. J Pharmacol Exp Ther 1973; 185: 642-8.
50. Spector R, Lorenzo AV. The effects of salicylate and probenecid on the cerebrospinal fluid transport of penicillin, aminosalicyclic acid and iodide. J Pharmacol Exp Ther 1974; 188: 55-65.